Cargando…

Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study

INTRODUCTION: Dipeptidyl peptidase-3 (DPP3) is a protease involved in the degradation of several cardiovascular mediators. Adrenomedullin (bio-ADM) is a peptide essential for regulation of endothelial barrier function. In different shock-pathologies, both biomarkers are associated with disease sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Lier, Dirk, Deniau, Benjamin, Santos, Karine, Hartmann, Oliver, Dudoignon, Emmanuel, Depret, François, Plaud, Benoit, Laterre, Pierre-Francois, Mebazaa, Alexandre, Pickkers, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571166/ https://www.ncbi.nlm.nih.gov/pubmed/36628268 http://dx.doi.org/10.1183/23120541.00342-2022

Ejemplares similares

Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3
por: van Lier, D., et al.
Publicado: (2020)

Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study
por: Blet, Alice, et al.
Publicado: (2021)

Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients
por: Dépret, François, et al.
Publicado: (2020)

Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: Post-hoc analyses of the phase II adrenomedullin and outcome in septic shock 2 trial
por: van Lier, Dirk, et al.
Publicado: (2022)

Three-month quality of life in survivors of ARDS due to COVID-19: A preliminary report from a French academic centre
por: Valent, Arnaud, et al.
Publicado: (2020)

A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)
por: Geven, Christopher, et al.
Publicado: (2019)

Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept study
por: Deniau, Benjamin, et al.
Publicado: (2020)

Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-19
por: Caméléna, François, et al.
Publicado: (2021)

Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort
por: Dellière, Sarah, et al.
Publicado: (2021)

Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study
por: Mebazaa, Alexandre, et al.
Publicado: (2018)

Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19
por: Dudoignon, Emmanuel, et al.
Publicado: (2020)

Combination of Mycological Criteria: a Better Surrogate to Identify COVID-19-Associated Pulmonary Aspergillosis Patients and Evaluate Prognosis?
por: Dellière, Sarah, et al.
Publicado: (2022)

Alteration of the Renin–Angiotensin–Aldosterone System in Shock: Role of the Dipeptidyl Peptidase 3
por: Picod, Adrien, et al.
Publicado: (2021)

Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats
por: Blet, Alice, et al.
Publicado: (2019)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Adrenomedullin in heart failure: pathophysiology and therapeutic application
por: Voors, Adriaan A., et al.
Publicado: (2018)

Added value of serial bio-adrenomedullin measurement in addition to lactate for the prognosis of septic patients admitted to ICU
por: Blet, Alice, et al.
Publicado: (2020)

Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis
por: Geven, Christopher, et al.
Publicado: (2018)

Circulating dipeptidyl peptidase (cDPP3)—A marker for end‐stage heart failure?
por: Pavo, Noemi, et al.
Publicado: (2022)

Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials
por: Daghmouri, Mohamed Aziz, et al.
Publicado: (2023)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
por: Jaenisch, Simone E., et al.
Publicado: (2022)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome
por: Arrigo, Mattia, et al.
Publicado: (2019)

Continuous Lower Abdominal Compression as a Therapeutic Intervention in COVID-19 ARDS
por: Cupaciu, Alexandru, et al.
Publicado: (2021)

Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial
por: Takagi, Koji, et al.
Publicado: (2021)

The mechanism of action of the adrenomedullin-binding antibody adrecizumab
por: Geven, Christopher, et al.
Publicado: (2018)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Low total cholesterol blood level is correlated with pulmonary severity in COVID-19 critical ill patients
por: Ressaire, Quentin, et al.
Publicado: (2020)

Predictive Performance of Neutrophil Gelatinase Associated Lipocalin, Liver Type Fatty Acid Binding Protein, and Cystatin C for Acute Kidney Injury and Mortality in Severely Ill Patients
por: Asakage, Ayu, et al.
Publicado: (2024)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
por: Torrecillas-Baena, Bárbara, et al.
Publicado: (2023)

Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial
por: Laterre, Pierre-François, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8edg2g0mpggl9ofpsrdg9acvik